272 related articles for article (PubMed ID: 34921019)
1. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
[TBL] [Abstract][Full Text] [Related]
3. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
4. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
[TBL] [Abstract][Full Text] [Related]
6. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
7. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Mao G; Mu Z; Wu DA
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
9. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
10. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
11. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
[TBL] [Abstract][Full Text] [Related]
12.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
13. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
[TBL] [Abstract][Full Text] [Related]
14. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
Jiang W; Zhang W; Wu L; Liu L; Men Y; Wang J; Liang J; Hui Z; Zhou Z; Bi N; Wang L
Biomed Res Int; 2017; 2017():6501385. PubMed ID: 28280736
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
Li W; Li C; Ma L; Jin F
Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
[TBL] [Abstract][Full Text] [Related]
18. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
[TBL] [Abstract][Full Text] [Related]
19. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]